ExpertiseUpdated on 12 May 2025
NUBINNO CONNECT – Pharma B2B platform
About
NUBINNO CONNECT is a digital B2B platform that enables seamless collaboration in the pharmaceutical industry. It connects manufacturers, CDMOs, product developers, and distributors across borders, supporting licensing, distribution, and co-development deals. Built on industry expertise , the platform provides a structured environment to accelerate business partnerships. Release 1.0 launches in Q4 2025.
Organisation
Similar opportunities
Partnership
Strategic partnership opportunities for scaling a digital pharma platform
- Others
- Implementation phase
Mariusz Wituszynski
Investor Relations at Nubinno Connect
Warsaw, Poland
Project cooperation
Horizon Europe: Digital pharma marketplace for licensing & distribution
Mariusz Wituszynski
Investor Relations at Nubinno Connect
Warsaw, Poland
Project cooperation
- Partner seeks Consortium/Coordinator
- Consortium/Coordinator seeks Partners
- HORIZON-HLTH-2025-01-TOOL-02: Advancing cell secretome-based therapies
- Cluster Food (CL6): HORIZON-CL6-2025-02-FARM2FORK-12 Nutrition and Mental Health
- HORIZON-CL4-2025-03-HUMAN-18: GenAI4EU central Hub (CSA) (AI/Data/Robotics Partnership)
- HORIZON-HLTH-2025-03-TOOL-01-two-stage: Enhancing cell therapies with genomic techniques
- HORIZON-HLTH-2025-01-IND-01: Optimising the manufacturing of Advanced Therapy Medicinal Products (ATMPs)
- HORIZON-CL4-2025-04-DATA-03: Software Engineering for AI and generative AI (RIA) (AI/Data/Robotics Partnership)
- HORIZON-CL4-2025-04-DIGITAL-EMERGING-06: Challenge-Driven GenAI4EU Booster (RIA) (AI/Data/Robotics Partnership)
- HORIZON-CL4-2025-03-DATA-13: Fostering Innovative and Compliant Data Ecosystems (IA) (AI, Data and Robotics Partnership)
- Cluster Health (CL1): HORIZON-HLTH-2025-01-DISEASE-04: Leveraging artificial intelligence for pandemic preparedness and response
- HORIZON-CL4-2025-04-DATA-02: Empowering AI/generative AI along the Cognitive Computing continuum (RIA) (AI/Data/Robotics Partnership)
- HORIZON-HLTH-2025-01-IND-02: Digitalisation of conformity assessment procedures of medical devices and in vitro diagnostic medical devices
- Cluster Health (CL1): HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage: Advancing knowledge on the impacts of micro- and nanoplastics on human health
- Cluster Health (CL1): HORIZON-HLTH-2025-01-CARE-01: End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU)
- Cluster Health (CL1): HORIZON-HLTH-2025-03-ENVHLTH-01-two-stage: The impact of pollution on the development and progression of brain diseases and disorders
- Cluster Health (CL1): HORIZON-HLTH-2025-03-DISEASE-02-two-stage: Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders
- Cluster Health (CL1): HORIZON-HLTH-2025-03-STAYHLTH-01-two-stage: Improving the quality of life of persons with intellectual disabilities and their families
- HORIZON-HLTH-2025-01-IND-03: Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative (“breakthrough”) devices
- Cancer Mission: HORIZON-MISS-2025-02-CANCER-02: Understanding the effects of environmental exposure on the risk of paediatric, adolescent and young adult cancers
- HORIZON-HLTH-2025-01-DISEASE-03: Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential
- HORIZON-HLTH-2025-01-DISEASE-01: Randomised controlled trials to test safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections
- Cluster Health (CL1): HORIZON-HLTH-2025-01-TOOL-03: Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU)
- HORIZON-HLTH-2025-03-DISEASE-06-two-stage: Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD)
Robert Lugowski
CEO at CliniNote